Background: NAFLD has become one the most frequent liver disease in western countries. It is
associated with Metabolic Syndrome, insulin resistance and diabetes. As well as the
abovementioned conditions, it represents, a cardiovascular risk factor. Some evidences
have demonstrated that Endothelial Dysfunction (ED),the pathophysiological basis of
Cardiovascular Diseases (CVD),is present also in a part of NAFLD pts. ED can be evaluated
in its “preclinical” status by performing vascular reactivity studies,such as Peripheral
Artery Tonometry (PAT). However, not all NAFLD patients have a clinically demonstrable
ED or a higher CVD risk. Untargeted Metabolomics is a novel and powerful method to
discover biomarkers and give insights on diseases pathophysiology.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Digestive and Liver DiseaseAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2019 Published by Elsevier Inc.
